- Home
- SWKH vs FULC Comparison
SWKH vs FULC Comparison
Compare SWKH & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWKH
- FULC
- Stock Information
- Founded
- SWKH 1996
- FULC 2015
- Country
- SWKH United States
- FULC United States
- Employees
- SWKH N/A
- FULC N/A
- Industry
- SWKH Diversified Financial Services
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- SWKH Finance
- FULC Health Care
- Exchange
- SWKH Nasdaq
- FULC Nasdaq
- Market Cap
- SWKH 210.8M
- FULC 221.5M
- IPO Year
- SWKH 1999
- FULC 2019
- Fundamental
- Price
- SWKH $16.10
- FULC $3.01
- Analyst Decision
- SWKH
- FULC Hold
- Analyst Count
- SWKH 0
- FULC 10
- Target Price
- SWKH N/A
- FULC $7.44
- AVG Volume (30 Days)
- SWKH 7.1K
- FULC 727.6K
- Earning Date
- SWKH 11-14-2024
- FULC 11-13-2024
- Dividend Yield
- SWKH N/A
- FULC N/A
- EPS Growth
- SWKH N/A
- FULC N/A
- EPS
- SWKH 0.84
- FULC N/A
- Revenue
- SWKH $24,725,000.00
- FULC $80,871,000.00
- Revenue This Year
- SWKH N/A
- FULC $2,821.96
- Revenue Next Year
- SWKH $6.17
- FULC N/A
- P/E Ratio
- SWKH $19.19
- FULC N/A
- Revenue Growth
- SWKH N/A
- FULC 2987.86
- 52 Week Low
- SWKH $15.77
- FULC $2.87
- 52 Week High
- SWKH $18.75
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- SWKH 37.07
- FULC 32.66
- Support Level
- SWKH $16.17
- FULC $3.38
- Resistance Level
- SWKH $17.10
- FULC $3.94
- Average True Range (ATR)
- SWKH 0.48
- FULC 0.21
- MACD
- SWKH -0.03
- FULC 0.05
- Stochastic Oscillator
- SWKH 15.44
- FULC 5.55
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.